<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02331589</url>
  </required_header>
  <id_info>
    <org_study_id>AFEKRG</org_study_id>
    <nct_id>NCT02331589</nct_id>
  </id_info>
  <brief_title>Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis</brief_title>
  <official_title>Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chuncheon Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chuncheon Sacred Heart Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Korea red ginseng (KRG) has anti-carcinogenic activity, anti-oxidant activity,
      and cancer related anti-fatigue.

      Methods: Seventy five patients with non-alcoholic hepatitis were prospectively randomized to
      receive 3 weeks of KRG or placebo. Liver function test, pro-inflammatory cytokines,
      adiponectin, fatigue severity scale, and antioxidant activity were check and compared.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fatigue Severity Scale

      We used to be KRUPP's fatigue severity scale. The survey has nine questions as following:
      (1) my motivation is lower, when I am fatigued (2) exercise brings on my fatigue (3) I am
      easily fatigued (4) fatigue interferes with my physical functioning (5) fatigue causes
      frequent problems for me (6) my fatigue prevents sustained physical functioning (7) fatigue
      interferes with carrying out certain duties and responsibilities (8) fatigue is among my 3
      most disabling symptoms (9) fatigue interferes with my work, family, or social life. All
      subjects scored each question on a 7-point scale (1 = strongly disagree to 4 = neither
      disagree nor agree to 7 = strongly agree). All fatigue severity scale calculated and
      collected by one research nurse (C.W.K) in the Department of Internal Medicine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Liver Enzymes</measure>
    <time_frame>3 weeks of KRG</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue as Measured by KRUPP's Fatigue Severity Scale</measure>
    <time_frame>3 weeks of KRG</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>KRUPP's fatigue severity scale.
The survey has nine questions as following:
my motivation is lower, when I am fatigued
exercise brings on my fatigue
I am easily fatigued
fatigue interferes with my physical functioning
fatigue causes frequent problems for me
my fatigue prevents sustained physical functioning
fatigue interferes with carrying out certain duties and responsibilities
fatigue is among my 3 most disabling symptoms
fatigue interferes with my work, family, or social life. All subjects scored each question on a 7-point scale (1 = strongly disagree to 4 = neither disagree nor agree to 7 = strongly agree).
Scores range from 9 to 63, with higher scores indicating higher fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pro-inflammatory Cytokine</measure>
    <time_frame>3 weeks of KRG</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>tumor necrosis factor-alpha, interleukin-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>3 weeks of KRG</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>Korea Red Ginseng (KRG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>KRG capsule (3,000 mg/day) for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (for KRG)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (for KRG) for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRG (Korea Red ginseng)</intervention_name>
    <description>3 weeks of KRG capsule (3,000 mg/day)</description>
    <arm_group_label>Korea Red Ginseng (KRG)</arm_group_label>
    <other_name>Korea Red ginseng capsule (3,000 mg/day)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for KRG)</intervention_name>
    <description>Placebos with same shape and size were manufactured and at Korea Ginseng Corporation</description>
    <arm_group_label>Placebo (for KRG)</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aspartate aminotransferase (AST) ≥ 50 U/L or alanine aminotransferase (ALT) ≥ 50 U/L,
             and Fatty liver or Hepatitis

        Exclusion Criteria:

          -  viral hepatitis, alcoholic hepatitis, autoimmune hepatitis, pancreatitis,
             hemochromatosis, Wilson's disease, drug induced liver injury, or cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>February 8, 2015</lastchanged_date>
  <firstreceived_date>December 31, 2014</firstreceived_date>
  <firstreceived_results_date>January 7, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chuncheon Sacred Heart Hospital</investigator_affiliation>
    <investigator_full_name>Ki Tae Suk</investigator_full_name>
    <investigator_title>doctor, assistant professor</investigator_title>
  </responsible_party>
  <keyword>Fatigue</keyword>
  <keyword>Panax ginseng</keyword>
  <keyword>Chronic hepatitis</keyword>
  <keyword>Non-alcoholic Fatty Liver Disease</keyword>
  <keyword>Adiponectin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Korea Red Ginseng (KRG)</title>
          <description>KRG capsule (3,000 mg/day) for 3 weeks
KRG (Korea Red ginseng): 3 weeks of KRG capsule (3,000 mg/day)</description>
        </group>
        <group group_id="P2">
          <title>Placebo (for KRG)</title>
          <description>placebo (for KRG) for 3 weeks
Placebo (for KRG): Placebos with same shape and size were manufactured and at Korea Ginseng Corporation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Korea Red Ginseng (KRG)</title>
          <description>KRG capsule (3,000 mg/day) for 3 weeks
KRG (Korea Red ginseng): 3 weeks of KRG capsule (3,000 mg/day)</description>
        </group>
        <group group_id="B2">
          <title>Placebo (for KRG)</title>
          <description>placebo (for KRG) for 3 weeks
Placebo (for KRG): Placebos with same shape and size were manufactured and at Korea Ginseng Corporation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="65"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="58"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="45.8" spread="12.7"/>
                <measurement group_id="B2" value="50.0" spread="12.8"/>
                <measurement group_id="B3" value="47.8" spread="12.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="53"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Korea, Republic of</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="65"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Liver Enzymes</title>
        <description>aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase</description>
        <time_frame>3 weeks of KRG</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Korea Red Ginseng (KRG)</title>
            <description>KRG capsule (3,000 mg/day) for 3 weeks
KRG (Korea Red ginseng): 3 weeks of KRG capsule (3,000 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for KRG)</title>
            <description>placebo (for KRG) for 3 weeks
Placebo (for KRG): Placebos with same shape and size were manufactured and at Korea Ginseng Corporation</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Liver Enzymes</title>
            <description>aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase</description>
            <units>U/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>aspartate aminotransferase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52.1" spread="30.7"/>
                  <measurement group_id="O2" value="59.1" spread="37.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>alanine aminotransferase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="81.0" spread="43.7"/>
                  <measurement group_id="O2" value="81.6" spread="32.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>gamma glutamyl transferase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="106.9" spread="68.6"/>
                  <measurement group_id="O2" value="139.3" spread="198.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>lactate dehydrogenase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="226.7" spread="99.0"/>
                  <measurement group_id="O2" value="218.6" spread="34.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue as Measured by KRUPP’s Fatigue Severity Scale</title>
        <description>KRUPP’s fatigue severity scale.
The survey has nine questions as following:
my motivation is lower, when I am fatigued
exercise brings on my fatigue
I am easily fatigued
fatigue interferes with my physical functioning
fatigue causes frequent problems for me
my fatigue prevents sustained physical functioning
fatigue interferes with carrying out certain duties and responsibilities
fatigue is among my 3 most disabling symptoms
fatigue interferes with my work, family, or social life. All subjects scored each question on a 7-point scale (1 = strongly disagree to 4 = neither disagree nor agree to 7 = strongly agree).
Scores range from 9 to 63, with higher scores indicating higher fatigue</description>
        <time_frame>3 weeks of KRG</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Korea Red Ginseng (KRG)</title>
            <description>KRG capsule (3,000 mg/day) for 3 weeks
KRG (Korea Red ginseng): 3 weeks of KRG capsule (3,000 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for KRG)</title>
            <description>placebo (for KRG) for 3 weeks
Placebo (for KRG): Placebos with same shape and size were manufactured and at Korea Ginseng Corporation</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Fatigue as Measured by KRUPP’s Fatigue Severity Scale</title>
            <description>KRUPP’s fatigue severity scale.
The survey has nine questions as following:
my motivation is lower, when I am fatigued
exercise brings on my fatigue
I am easily fatigued
fatigue interferes with my physical functioning
fatigue causes frequent problems for me
my fatigue prevents sustained physical functioning
fatigue interferes with carrying out certain duties and responsibilities
fatigue is among my 3 most disabling symptoms
fatigue interferes with my work, family, or social life. All subjects scored each question on a 7-point scale (1 = strongly disagree to 4 = neither disagree nor agree to 7 = strongly agree).
Scores range from 9 to 63, with higher scores indicating higher fatigue</description>
            <units>scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33.0" spread="11.6"/>
                  <measurement group_id="O2" value="29.8" spread="14.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pro-inflammatory Cytokine</title>
        <description>tumor necrosis factor-alpha, interleukin-6</description>
        <time_frame>3 weeks of KRG</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Korea Red Ginseng (KRG)</title>
            <description>KRG capsule (3,000 mg/day) for 3 weeks
KRG (Korea Red ginseng): 3 weeks of KRG capsule (3,000 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for KRG)</title>
            <description>placebo (for KRG) for 3 weeks
Placebo (for KRG): Placebos with same shape and size were manufactured and at Korea Ginseng Corporation</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pro-inflammatory Cytokine</title>
            <description>tumor necrosis factor-alpha, interleukin-6</description>
            <units>pg/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>tumor necrosis factor-alpha</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="108.0" spread="54.8"/>
                  <measurement group_id="O2" value="123.1" spread="42.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>interleukin-6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.3" spread="1.9"/>
                  <measurement group_id="O2" value="1.5" spread="0.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adiponectin</title>
        <description>enzyme-linked immunosorbent assay</description>
        <time_frame>3 weeks of KRG</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Korea Red Ginseng (KRG)</title>
            <description>KRG capsule (3,000 mg/day) for 3 weeks
KRG (Korea Red ginseng): 3 weeks of KRG capsule (3,000 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for KRG)</title>
            <description>placebo (for KRG) for 3 weeks
Placebo (for KRG): Placebos with same shape and size were manufactured and at Korea Ginseng Corporation</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adiponectin</title>
            <description>enzyme-linked immunosorbent assay</description>
            <units>pg/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7751.2" spread="3108.1"/>
                  <measurement group_id="O2" value="7711.6" spread="3041.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious and Other (Not Including Serious) Adverse Events were not collected/assessed</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Korea Red Ginseng (KRG)</title>
          <description>KRG capsule (3,000 mg/day) for 3 weeks
KRG (Korea Red ginseng): 3 weeks of KRG capsule (3,000 mg/day)</description>
        </group>
        <group group_id="E2">
          <title>Placebo (for KRG)</title>
          <description>placebo (for KRG) for 3 weeks
Placebo (for KRG): Placebos with same shape and size were manufactured and at Korea Ginseng Corporation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ki Tae Suk</name_or_title>
      <organization>Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea</organization>
      <phone>+82-33-240-5826</phone>
      <email>ktsuk@hallym.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
